Browsing Category
Pharma Industry News
4736 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Can Alnylam Pharmaceuticals’ vutrisiran reverse cardiac damage? HELIOS-B Phase 3 ATTR-CM trial says yes
New HELIOS-B data shows vutrisiran improves cardiac structure and kidney outcomes in ATTR-CM. Find out how Alnylam’s RNAi drug is reshaping treatment.
Is the FDA’s hold on Intellia a warning sign for in vivo CRISPR delivery across biotech?
Intellia’s nex-z trials face FDA hold after liver safety event. Learn how its extended cash runway to mid-2027 could reshape biotech investor confidence.
Anthem Biosciences (NSE: ANTHEM) Q2 FY26 results: Can strong CRDMO tailwinds keep driving profitability?
Anthem Biosciences Q2 FY26 results reveal strong CRDMO-led growth and 44.5% EBITDA margins. Find out what’s driving investor sentiment and what’s next.
Can povetacicept reshape autoimmune kidney care? Vertex Pharmaceuticals’ RUBY-3 trial shows promise
Vertex’s RUBY-3 trial shows strong 48-week data for povetacicept in IgAN and pMN. Find out how this sets the stage for late-stage trials and regulatory filings.
Breakthrough REZOLVE-AD results position Rezpegaldesleukin as a potential first-in-class IL-2 Treg therapy for atopic dermatitis and asthma
Rezpegaldesleukin delivers strong dual skin and asthma results in the REZOLVE-AD study — find out how Nektar Therapeutics plans to advance its IL-2 Treg platform in 2026.
Pfizer sweetens Metsera acquisition offer to secure board approval and fend off Novo Nordisk challenge
Find out how Pfizer’s amended $86.25-per-share merger with Metsera reshapes the obesity-drug race and signals Big Pharma’s shifting acquisition strategy.
AHA 2025 spotlight: sotagliflozin data spark debate on benefits in HFpEF patients without diabetes
Find out how sotagliflozin’s debated HFpEF results at AHA 2025 could change heart-failure therapy beyond diabetes.
Metsera picked Pfizer over Novo Nordisk — here’s what swung the $10bn deal
Pfizer secures obesity biotech Metsera for $10 billion after regulatory pushback sidelines Novo Nordisk. Find out what this means for pharma M&A now.
How CRISPR Therapeutics’ one-and-done CTX310 therapy could transform treatment for high cholesterol and triglycerides
Find out how CRISPR Therapeutics’ CTX310 gene-editing therapy achieved profound cholesterol and triglyceride reductions — could it reshape cardiovascular care?
Telitacicept delivers breakthrough proteinuria decline in Chinese IgA nephropathy phase 3 study
Find out how RemeGen’s Telitacicept achieved phase 3 success in reducing proteinuria for IgA nephropathy patients in China.